Home / Science
Science
Why a monogenic form of Alzheimer’s disease is a gene-therapy target, and how the programme works.
While the underlying cause for the vast majority of Alzheimer’s Disease (AD) is not well understood, a rare subset of AD is caused by autosomal dominant mutations in one of three genes — presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP), with PSEN1 mutations accounting for 70–80% of all cases.
While sporadic AD typically occurs later in life, patients with Autosomal Dominant Alzheimer’s Disease (ADAD) typically show signs of cognitive impairment before the age of 65. Although ADAD accounts for <1% of all AD, the monogenic etiology of this disorder provides an opportunity for a gene therapy approach to slow or halt disease progression. To this end we are developing a gene therapy to treat ADAD patients harboring a mutation in the PSEN1 gene.
The biology
The presenilin 1 protein (PS-1) is the catalytic subunit of a tetrameric aspartyl protease known as the γ-secretase complex, which is responsible for proteolysis of several substrates including the amyloid precursor protein (APP). Proteolytic processing of APP leads to the generation of several peptide fragments including Aβ, the primary component of amyloid deposits in the brain of AD patients.
More than 100 different mutations have been identified in the PSEN1 gene which are causative for ADAD. Essentially all PSEN1 mutations have been shown to result in a loss of function of γ-secretase activity, decreased production of total Aβ and disruption of several cellular homeostatic processes. Although total Aβ production is decreased, there is an increase in the Aβ42/Aβ40 ratio, which is associated with an increase in the amount of amyloid deposited in the brains of ADAD patients.
While the role of amyloid deposition in AD progression remains controversial, the causative role of PSEN1 mutations in ADAD is unequivocal. Although the underlying PSEN1 mutations which cause early-onset ADAD are not present in sporadic late-onset AD, disease progression in terms of pathological biomarkers and clinical symptoms is nearly indistinguishable between the early and late-onset forms of the disease. The extensive body of work on the natural history of AD is therefore applicable to the rarer ADAD, and will help Paros Bio design and execute clinical studies.
The approach
Paros Bio is using the adeno-associated virus (AAV) platform to introduce a wildtype human PSEN1 gene into ADAD patients. AAV-mediated transduction and expression of a wildtype PS-1 protein in ADAD patient brain cells should ameliorate the impaired γ-secretase function caused by the mutant PSEN1.
We have demonstrated that introducing a wildtype copy of the PSEN1 gene into ADAD patient-derived cells can restore a functional γ-secretase complex.
Work is ongoing to demonstrate preclinical proof of concept with AAV development candidates in translational animal models. A genetically defined patient population and well-described disease biomarkers should enable a streamlined clinical proof-of-concept study and delivery of a first-in-class, life-changing therapy for ADAD patients.
The programme in four lines
PSEN1
Loss-of-function mutations in presenilin 1, the cause of 70–80% of ADAD.
AAV
An adeno-associated virus vector expressing a wildtype human PSEN1 gene.
γ-secretase
Restoring a functional γ-secretase complex in patient-derived cells.
Preclinical
Proof of concept with AAV development candidates in translational animal models.
Genetically defined
Patients harbouring PSEN1 mutations — a well-defined group for a streamlined study.
First in class
A therapy intended to slow or halt progression of ADAD.